Oxford’s Doug Altman Receives Lifetime Achievement Award
Altman has been instrumental in the development of “truly robust guidelines for the reporting of clinical trials and wider clinical research studies”.
Prof. Doug Altman, founding director of the Centre for Statistics in Medicine in Oxford, U.K. has received the 2015 BMJ Lifetime Achievement for his contribution to improving reporting of health research.
Altman has been instrumental in the development of “truly robust guidelines for the reporting of clinical trials and wider clinical research studies,” noted GSK’s Global Head of Epidemiology Dr. Andrew Roddam, who presented the award on behalf of the sponsors.
Dr Fiona Godlee, Editor-in-chief of the The BMJ, said Professor Altman “has done more than anyone else to encourage researchers to fully report what they actually did, warts and all, rather than letting the best be the enemy of the good or, worse, pretending that research is perfect.”
Click here for the full release about the BMJ award winners.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
